Literature DB >> 19854471

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.

David A Manly1, Jianguo Wang, Sam L Glover, Raj Kasthuri, Howard A Liebman, Nigel S Key, Nigel Mackman.   

Abstract

Cancer patients exhibit a high rate of thromboembolism (VTE). In this study, we analyzed levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE. Blood was collected from cancer patients within 24 h of objectively diagnosed VTE (n=53) and from cancer patients without VTE (n=13). MPs were isolated from platelet poor plasma by centrifugation at 20,000g for 15 min. MP TF activity was measured using a two-stage chromogenic assay. Cancer patients with VTE had a significantly higher mean MP TF activity compared with cancer patients without VTE (1.7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19854471      PMCID： PMC2878897          DOI： 10.1016/j.thromres.2009.09.019

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


  17 in total

1.  Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.

Authors:  Gregor Hron; Marietta Kollars; Heinz Weber; Verena Sagaster; Peter Quehenberger; Sabine Eichinger; Paul A Kyrle; Ansgar Weltermann
Journal:  Thromb Haemost       Date:  2007-01       Impact factor: 5.249

2.  The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients.

Authors:  Benilde Cosmi; Cristina Legnani; Michela Cini; Giuliana Guazzaloca; Gualtiero Palareti
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

Review 3.  Procoagulant microparticles: disrupting the vascular homeostasis equation?

Authors:  Olivier Morel; Florence Toti; Bénédicte Hugel; Babé Bakouboula; Laurence Camoin-Jau; Françoise Dignat-George; Jean-Marie Freyssinet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-21       Impact factor: 8.311

4.  Risk factors for venous thromboembolic events in cancer patients.

Authors:  K Kröger; D Weiland; C Ose; N Neumann; S Weiss; C Hirsch; K Urbanski; S Seeber; M E Scheulen
Journal:  Ann Oncol       Date:  2005-11-09       Impact factor: 32.976

5.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

6.  Microparticle-associated tissue factor activity: a link between cancer and thrombosis?

Authors:  M E T Tesselaar; F P H T M Romijn; I K Van Der Linden; F A Prins; R M Bertina; S Osanto
Journal:  J Thromb Haemost       Date:  2006-12-13       Impact factor: 5.824

7.  D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.

Authors:  Cihan Ay; Rainer Vormittag; Daniela Dunkler; Ralph Simanek; Alexandru-Laurentiu Chiriac; Johannes Drach; Peter Quehenberger; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

8.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.

Authors:  Vladimir Y Bogdanov; Viji Balasubramanian; James Hathcock; Oana Vele; Mark Lieb; Yale Nemerson
Journal:  Nat Med       Date:  2003-03-24       Impact factor: 53.440

9.  Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia.

Authors:  Omer Aras; Arun Shet; Ronald R Bach; Jessica L Hysjulien; Arne Slungaard; Robert P Hebbel; Gines Escolar; Bernd Jilma; Nigel S Key
Journal:  Blood       Date:  2004-02-26       Impact factor: 22.113

10.  Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.

Authors:  K Uno; S Homma; T Satoh; K Nakanishi; D Abe; K Matsumoto; A Oki; H Tsunoda; I Yamaguchi; T Nagasawa; H Yoshikawa; K Aonuma
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640
View more
  65 in total

Review 1.  Thrombosis and cancer.

Authors:  Annie Young; Oliver Chapman; Carole Connor; Christopher Poole; Peter Rose; Ajay K Kakkar
Journal:  Nat Rev Clin Oncol       Date:  2012-07-10       Impact factor: 66.675

2.  The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.

Authors:  Katrin F Nickel; Göran Ronquist; Florian Langer; Linda Labberton; Tobias A Fuchs; Carsten Bokemeyer; Guido Sauter; Markus Graefen; Nigel Mackman; Evi X Stavrou; Gunnar Ronquist; Thomas Renné
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

Review 3.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

4.  Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.

Authors:  B N Yamaja Setty; Nigel S Key; A Koneti Rao; Suhita Gayen-Betal; Suba Krishnan; Carlton D Dampier; Marie J Stuart
Journal:  Br J Haematol       Date:  2012-02-24       Impact factor: 6.998

5.  Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity.

Authors:  R D Lee; D A Barcel; J C Williams; J G Wang; J C Boles; D A Manly; N S Key; N Mackman
Journal:  Thromb Res       Date:  2011-07-06       Impact factor: 3.944

6.  Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure.

Authors:  R Todd Stravitz; Regina Bowling; Robert L Bradford; Nigel S Key; Sam Glover; Leroy R Thacker; Don A Gabriel
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

7.  Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an in vitro model of circulating tissue factor.

Authors:  Garth W Tormoen; Ayesha Khader; András Gruber; Owen J T McCarty
Journal:  Phys Biol       Date:  2013-04-15       Impact factor: 2.583

8.  Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).

Authors:  Jeffrey I Zwicker; Howard A Liebman; Kenneth A Bauer; Thomas Caughey; Federico Campigotto; Rachel Rosovsky; Simon Mantha; Craig M Kessler; Jonathan Eneman; Vidya Raghavan; Heinz-Joseph Lenz; Andrea Bullock; Elizabeth Buchbinder; Donna Neuberg; Bruce Furie
Journal:  Br J Haematol       Date:  2012-12-13       Impact factor: 6.998

9.  Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices.

Authors:  Angelo Nascimbene; Ruben Hernandez; Joggy K George; Anita Parker; Angela L Bergeron; Subhashree Pradhan; K Vinod Vijayan; Andrew Civitello; Leo Simpson; Maria Nawrot; Vei-Vei Lee; Hari R Mallidi; Reynolds M Delgado; Jing Fei Dong; O H Frazier
Journal:  J Heart Lung Transplant       Date:  2014-01-19       Impact factor: 10.247

Review 10.  Biomolecular markers of cancer-associated thromboembolism.

Authors:  Diana L Hanna; Richard H White; Ted Wun
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-21       Impact factor: 6.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.